Melbourne, Victoria, Australia
Trajan Scientific and Medical (Trajan) welcomed Minister for Jobs, Innovation and Trade, Martin Pakula at Trajan’s global corporate headquarters in Melbourne today to announce a grant supporting advanced scientific manufacturing in Victoria.
Trajan plans to invest circa A$2.4M into its Melbourne facility, with support from the Victorian Government over the next three years to meet growing global demand for its scientific products and technologies.
Stephen Tomisich, CEO, Trajan Scientific and Medical, says “We are pleased to engage the support of the Victorian Government, highlighting growth areas where Trajan is developing new devices and technologies to improve measurements for healthcare, food and environmental analysis.”
Trajan’s production will be scaled up through investment in sophisticated automation, manufacturing equipment, upskilling staff, and creation of new roles.
“Through continued investment into our team and infrastructure, the advanced manufacturing capability of our Melbourne facility is becoming a global benchmark for precision scientific technologies.” said Mr Tomisich.
This investment complements Trajan’s other centers of excellence, including unique polymer tubing extrusion operations in San Diego, USA; polymer production in Bethel, USA; glass manufacturing of analytical syringes and inlet liners in Penang, Malaysia, as well as Austin, USA.
Mr Tomisich said “At the heart of Trajan’s success is people - we firmly believe in developing our expertise in-house at all of our manufacturing and commercial locations around the world, as well as establishing relationships with partners that align with our commitment to improve human wellbeing.”
Trajan has a strong record of engagement with industry, academic and government partners around the globe, developing innovative analytical technologies and integrated laboratory workflow solutions.
“It’s about working together to translate scientific technologies to benefit people.” said Mr Tomisich.
Quotes attributable to Minister for Jobs, Innovation and Trade Martin Pakula
“We’re proud to be supporting local innovation, and improving patient care every step of the way.”
“Trajan’s choice to further develop its global HQ in Melbourne and expand its local manufacturing capability will strengthen Victoria’s global reputation as a thriving hub for biotechnology and pharmaceuticals.”
Photo: Mr Robert Lyon, Head of Corporate Development, Trajan Scientific and Medical, The Hon. Martin Pakula, Minister for Jobs, Innovation and Trade, Victorian Government, Mr Stephen Tomisich, Chief Executive Officer, Trajan Scientific and Medical, Dr Andrew Gooley, Chief Scientific Officer, Trajan Scientific and Medical, at Trajan’s global corporate headquarters in Melbourne, Australia.
Photo: The Hon. Martin Pakula, Minister for Jobs, Innovation and Trade, Victorian Government, welcomed by Mr Stephen Tomisich, Chief Executive Officer, Trajan Scientific and Medical.
Photo: Following the announcement, there was a demonstration of Trajan's hemaPEN by Ms Lada Staskova, RMIT Master of Applied Chemistry (by research) student and intern at Murdoch Children’s Research institute (MCRI), and Dr Wei Boon (Jason) Hon, Research Scientist and Blood Lab Manager, Trajan Scientific and Medical; presented by Dr Andrew Gooley, Chief Scientific Officer, Trajan Scientific and Medical.
Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.